Co-Authors
This is a "connection" page, showing publications co-authored by LEE M ELLIS and CATHY ENG.
Connection Strength
0.420
-
Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open. 2022 05 02; 5(5):e2213588.
Score: 0.055
-
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016 08 23; 7(34):54627-54631.
Score: 0.037
-
The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013; 8(10):e77117.
Score: 0.030
-
Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer. 2013 Dec 15; 119(24):4231-41.
Score: 0.030
-
Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: a case series. Acta Oncol. 2013 Jun; 52(5):1044-6.
Score: 0.028
-
Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. Cancer. 2012 Dec 15; 118(24):6188-98.
Score: 0.027
-
Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res. 2012 Jul 15; 18(14):3982-91.
Score: 0.027
-
GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis. 2012 Jul; 33(7):1327-31.
Score: 0.027
-
Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. Carcinogenesis. 2012 Apr; 33(4):841-7.
Score: 0.027
-
A novel platform for detection of CK+ and CK- CTCs. Cancer Discov. 2011 Dec; 1(7):580-6.
Score: 0.026
-
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010 Jan 20; 28(3):453-9.
Score: 0.023
-
Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):824-30.
Score: 0.022
-
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51.
Score: 0.021
-
Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007 Dec 15; 110(12):2761-7.
Score: 0.020
-
Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol. 2006 Jun; 29(3):219-24.
Score: 0.018